Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ

Clinical Breast Cancer

Volumn 8, Issue 3, 2008, Pages 275-280

  Partridge, Ann ^a,c   Winer, Jeffrey P ^a   Golshan, Mehra ^a   Bellon, Jennifer R ^a   Blood, Emily ^a   Dees, E Claire ^b   Sampson, Ebonie ^a   Emmons, Karen M ^a   Winer, Eric ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Emotional distress; Negative re excision; Noninvasive breast cancer; Risk perception

Indexed keywords

ARTICLE; BREAST CANCER; CARCINOMA IN SITU; CLINICAL PRACTICE; COHORT ANALYSIS; DOCTOR PATIENT RELATION; EMOTIONAL STRESS; HUMAN; INTRADUCTAL CARCINOMA; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRECANCER; RISK ASSESSMENT;

EID: 46949086246     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.032     Document Type: Article

References (30)

1. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913-8.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006; 56:168-83.
3. Yen TW, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 2004; 100:942-9.
4. Buchholz TA, Haffty BG, Harris JR. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. J Surg Oncol 2007; 95:610-3.
5. Patani N, Cutuli B, Mokbel K. Current management of DCIS: a review. Breast Cancer Res Treat 2007. Epub ahead of print.
6. Sakr R, Antoine M, Barranger E, et al. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma. Breast J 2008; 14:55-60.
7. Katz SJ, Lantz PM, Janz NK, et al. Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J Clin Oncol 2005; 23:3001-7.
8. De Morgan S, Redman S, White KJ, et al. "Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ. Health Expect 2002; 5:310-8.
9. Bluman LG, Borstelmann NA, Rimer BK, et al. Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med 2001; 10:589-98.
10. Rakovitch E, Franssen E, Kim J, et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003; 77:285-93.
11. van Gestel YR, Voogd AC, Vingerhoets AJ, et al. A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 2007; 43:549-56.
12. Partridge A, Adloff K, Blood E, et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008; 100:243-51.
13. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350:1430-41.
14. Eusebi V, Feudale E, Foschini MR et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994; 11:223-35.
15. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16:441-52.
16. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999; 353:1993-2000.
17. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451-67.
18. Bijker N, Rutgers EJ, Duchateau L, et al. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2001; 91:472-7.
19. Nakhlis F, Morrow M. Ductal carcinoma in situ. Surg Clin North Am 2003; 83:821-39.
20. Nakhlis F, Lazarus L, Hou N, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b NO invasive carcinoma. J Am Coll Surg 2005; 201:688-94.
21. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999; 340:1455-61.
22. Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 2007; 101:335-47.
23. Hughes L, Wang M, Page D, et al. Five year results of intergroup study E5194: local excision alone (without radiation treatment) for selected patients with ductal carcinoma in situ (DCIS). Breast Cancer Res Treat 2006; 100:s15 (Abstract 29).
24. Gail MH, Brinton LA, Byar DR et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-86.
25. Fobair P, Hoppe RT, Bloom J, et al. Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 1986; 4:805-14.
26. Veronesi P, Intra M, Vento AR, et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast 2005; 14:520-2.
27. Mabry H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg 2006; 192:455-7.
28. Yen TW Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management, of ductal carcinoma in situ. J Am Coll Surg 2005; 200:516-26.
29. El-Tamer M, Chun J, Gill M, et al. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohisto-chemical staining in ductal carcinoma in situ. Ann Surg Oncol 2005; 12:254-9.
30. Gilligan MA, Neuner J, Sparapani R, et al. Surgeon characteristics and variations in treatment for early-stage breast cancer. Arch Surg 2007; 142:17-22.